Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia.

Singh RS, Grayson W, Redston M, Diwan AH, Warneke CL, McKee PH, Lev D, Lyle S, Calonje E, Lazar AJ.

Am J Surg Pathol. 2008 Jun;32(6):936-42.

PMID:
18551751
2.
3.

An illustrative case of Muir-Torre syndrome: contribution of immunohistochemical analysis in identifying indicator sebaceous lesions.

Marazza G, Masouyé I, Taylor S, Prins C, Gaudin T, Saurat JH, French LE.

Arch Dermatol. 2006 Aug;142(8):1039-42.

PMID:
16924054
4.

Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.

Ponti G, Losi L, Pedroni M, Lucci-Cordisco E, Di Gregorio C, Pellacani G, Seidenari S.

J Invest Dermatol. 2006 Oct;126(10):2302-7. Epub 2006 Jul 6.

5.

Gene conversion is a frequent mechanism of inactivation of the wild-type allele in cancers from MLH1/MSH2 deletion carriers.

Zhang J, Lindroos A, Ollila S, Russell A, Marra G, Mueller H, Peltomaki P, Plasilova M, Heinimann K.

Cancer Res. 2006 Jan 15;66(2):659-64.

6.

Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families.

Ponti G, Ponz de Leon M, Losi L, Di Gregorio C, Benatti P, Pedroni M, Scarselli A, Riegler G, Lembo L, Pellacani G, Seidenari S, Rossi G, Roncucci L.

Br J Dermatol. 2005 Jun;152(6):1335-8. Review.

PMID:
15949004
7.

A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome.

Mangold E, Pagenstecher C, Leister M, Mathiak M, Rütten A, Friedl W, Propping P, Ruzicka T, Kruse R.

J Med Genet. 2004 Jul;41(7):567-72. No abstract available.

8.

Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias.

Kruse R, Rütten A, Schweiger N, Jakob E, Mathiak M, Propping P, Mangold E, Bisceglia M, Ruzicka T.

J Invest Dermatol. 2003 May;120(5):858-64.

9.

Loss of mismatch repair proteins in sebaceous gland tumors.

Popnikolov NK, Gatalica Z, Colome-Grimmer MI, Sánchez RL.

J Cutan Pathol. 2003 Mar;30(3):178-84.

PMID:
12641777
10.

Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome.

Machin P, Catasus L, Pons C, Muñoz J, Conde-Zurita JM, Balmaña J, Barnadas M, Martí RM, Prat J, Matias-Guiu X.

J Cutan Pathol. 2002 Aug;29(7):415-20.

PMID:
12139636
11.

Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test.

Mathiak M, Rütten A, Mangold E, Fischer HP, Ruzicka T, Friedl W, Propping P, Kruse R.

Am J Surg Pathol. 2002 Mar;26(3):338-43.

PMID:
11859205
12.

Molecular pathologic analysis enhances the diagnosis and management of Muir-Torre syndrome and gives insight into its underlying molecular pathogenesis.

Southey MC, Young MA, Whitty J, Mifsud S, Keilar M, Mead L, Trute L, Aittomäki K, McLachlan SA, Debinski H, Venter DJ, Armes JE.

Am J Surg Pathol. 2001 Jul;25(7):936-41.

PMID:
11420466
13.

"Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation.

Kruse R, Rütten A, Hosseiny-Malayeri HR, Bisceglia M, Friedl W, Propping P, Ruzicka T, Mangold E.

J Invest Dermatol. 2001 Mar;116(3):463-5.

14.

Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome.

Entius MM, Keller JJ, Drillenburg P, Kuypers KC, Giardiello FM, Offerhaus GJ.

Clin Cancer Res. 2000 May;6(5):1784-9.

15.
16.

Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors.

Marcus VA, Madlensky L, Gryfe R, Kim H, So K, Millar A, Temple LK, Hsieh E, Hiruki T, Narod S, Bapat BV, Gallinger S, Redston M.

Am J Surg Pathol. 1999 Oct;23(10):1248-55.

PMID:
10524526
17.

A novel germline mutation in the hMLH1 DNA mismatch repair gene in a patient with an isolated cystic sebaceous tumor.

Kruse R, Rütten A, Malayeri HR, Günzl HJ, Friedl W, Propping P.

J Invest Dermatol. 1999 Jan;112(1):117-8. No abstract available.

18.

Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria.

Kruse R, Rütten A, Lamberti C, Hosseiny-Malayeri HR, Wang Y, Ruelfs C, Jungck M, Mathiak M, Ruzicka T, Hartschuh W, Bisceglia M, Friedl W, Propping P.

Am J Hum Genet. 1998 Jul;63(1):63-70. Erratum in: Am J Hum Genet 1998 Oct;63(4):1252.

19.

The Muir-Torre syndrome: a 25-year retrospect.

Schwartz RA, Torre DP.

J Am Acad Dermatol. 1995 Jul;33(1):90-104. Review.

PMID:
7601953
20.

Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face.

Muir EG, Bell AJ, Barlow KA.

Br J Surg. 1967 Mar;54(3):191-5. No abstract available.

PMID:
6020987

Supplemental Content

Support Center